These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 8773037

  • 1. Jaundice due to anti-tuberculous drugs--a dose related phenomenon.
    Mirchandani LV, Joshi JM.
    J Assoc Physicians India; 1995 Nov; 43(11):767-9. PubMed ID: 8773037
    [Abstract] [Full Text] [Related]

  • 2. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W, Nagayama N, Miyamoto M, Hara H, Suzuki J, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H.
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [Abstract] [Full Text] [Related]

  • 3. HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone free anti-tuberculosis treatment in Yaounde, Cameroon.
    Kuaban C, Bercion R, Koulla-Shiro S.
    East Afr Med J; 1997 Aug; 74(8):474-7. PubMed ID: 9487410
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis.
    Park IN, Hong SB, Oh YM, Kim MN, Lim CM, Lee SD, Koh Y, Kim WS, Kim DS, Kim WD, Shim TS.
    J Antimicrob Chemother; 2006 Sep; 58(3):701-4. PubMed ID: 16857689
    [Abstract] [Full Text] [Related]

  • 5. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL, Xie YG, Tan WG, Chu NH, Li L, You YH, Yang YZ, Wang XM, Yan XL, Miao ZP, Duanmu HJ.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [Abstract] [Full Text] [Related]

  • 6. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [Abstract] [Full Text] [Related]

  • 7. Risk factors for adverse drug reactions during thiacetazone treatment of pulmonary tuberculosis in human immunodeficiency virus infected adults.
    Okwera A, Johnson JL, Vjecha MJ, Wolski K, Whalen CC, Hom D, Huebner R, Mugerwa RD, Ellner JJ.
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):441-5. PubMed ID: 9441099
    [Abstract] [Full Text] [Related]

  • 8. [Agranulocytosis due to anti-tuberculosis drugs including isoniazid (INH) and rifampicin (RFP)--a report of four cases and review of the literature].
    Shishido Y, Nagayama N, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Komatsu H, Yotsumoto H.
    Kekkaku; 2003 Nov; 78(11):683-9. PubMed ID: 14672045
    [Abstract] [Full Text] [Related]

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 10. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK, Kim JH, Kang H, Cho JS, Smego RA.
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [Abstract] [Full Text] [Related]

  • 11. [Multidrug-resistant tuberculosis. 4. Treatment and prognosis of multidrug-resistant tuberculosis].
    Ogawara M, Sakatani M.
    Kekkaku; 1998 Nov; 73(11):673-7. PubMed ID: 9866930
    [Abstract] [Full Text] [Related]

  • 12. [Tuberculosis and cancer: primary lung cancer cases after treatment with anti-tuberculous drugs].
    Sato H, Kayaba K, Oizumi K, Motomiya M.
    Kekkaku; 1989 Jul; 64(7):465-9. PubMed ID: 2585947
    [Abstract] [Full Text] [Related]

  • 13. Antibiotic therapy: a major cause of drug-induced jaundice in southwest England.
    Hussaini SH, O'Brien CS, Despott EJ, Dalton HR.
    Eur J Gastroenterol Hepatol; 2007 Jan; 19(1):15-20. PubMed ID: 17206072
    [Abstract] [Full Text] [Related]

  • 14. [Treatment of non-tuberculous pulmonary mycobacteriosis].
    Sakatani M, Nakajima Y.
    Kekkaku; 2006 Jan; 81(1):35-50. PubMed ID: 16479999
    [Abstract] [Full Text] [Related]

  • 15. [Tuberculosis and jaundice. Study of 103 cases].
    Pilheu JA, De Salvo MC, Barcat JA, Koch OR.
    Medicina (B Aires); 1987 Jan; 47(1):13-9. PubMed ID: 3613966
    [No Abstract] [Full Text] [Related]

  • 16. [Pyrazinamide-containing initial intensive short course chemotherapy of pulmonary tuberculosis].
    Wada M.
    Kekkaku; 1997 Oct; 72(10):587-95. PubMed ID: 9386358
    [Abstract] [Full Text] [Related]

  • 17. Current HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone-free antituberculosis treatment in Yaounde, Cameroon.
    Kuaban C, Bercion R, Koula-Shiro S.
    Cent Afr J Med; 1998 Feb; 44(2):34-7. PubMed ID: 9675969
    [Abstract] [Full Text] [Related]

  • 18. NTP Toxicology and Carcinogenesis Studies of 3,4-Dihydrocoumarin (CAS No. 119-84-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 423():1-336. PubMed ID: 12616288
    [Abstract] [Full Text] [Related]

  • 19. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
    Int J Tuberc Lung Dis; 1997 Dec; 1(6):509-17. PubMed ID: 9487448
    [Abstract] [Full Text] [Related]

  • 20. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.